SCOTT HELMS: Open Payments
NPI 1033229638 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,238 in 51 payments from 27 companies in 2025. Trend: 2023 $926 · 2024 $908 · 2025 $1,238
Food & beverage: $1,238
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $115 |
| Novartis Pharmaceuticals Corporation | 4 | $107 |
| GENZYME CORPORATION | 2 | $90 |
| AstraZeneca Pharmaceuticals LP | 3 | $76 |
| Legend Biotech USA Inc. | 3 | $71 |
| Eisai Inc. | 3 | $66 |
| Janssen Biotech, Inc. | 3 | $66 |
| Gilead Sciences, Inc. | 3 | $65 |
| GlaxoSmithKline, LLC. | 3 | $65 |
| BeOne Medicines USA, Inc. | 2 | $55 |
Products named: Enhertu, AYVAKIT, CARVYKTI, Lenvima, Trodelvy, EPKINLY, KISQALI, BRUKINSA.
Industry payments across GA — which companies pay providers there.
